Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

China Approves Geneseeq's PanTRKare as Companion Diagnostic for VELMARTO

14 August 2026 · By · Wire by Fusion42

Published

14 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biopharmaapac.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

China's NMPA approved Geneseeq's PanTRKare as a companion diagnostic for Vcare PharmaTech's next-generation TRK inhibitor Eratrectinib (VELMARTO), enabling precise detection of NTRK fusion-positive solid tumors and supporting early targeted therapy.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now tap into China's oncology diagnosis-treatment chain more effectively as the regulatory shortcut for companion diagnostics speeds patient access to advanced targeted therapies like VELMARTO.

◆ Coverage

1 source · 14 Aug 2026

◆ Related on Wire

◆ Topics

Biotechdiagnosticsoncologyregulatory-approvalchinapartner-ecosystem